STOCK TITAN

VistaGen Therapeutics Inc - VTGN STOCK NEWS

Welcome to our dedicated news page for VistaGen Therapeutics (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on VistaGen Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VistaGen Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VistaGen Therapeutics's position in the market.

Rhea-AI Summary
Vistagen Therapeutics announces pricing of $100 million underwritten offering of its common stock and warrants, led by BVF Partners LP and other institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.85%
Tags
none
-
Rhea-AI Summary
Vistagen's PH80 nasal spray showed statistically and clinically significant improvement in a Phase 2A study for premenstrual dysphoric disorder (PMDD). The spray demonstrated improvement in negative mood and physical and behavioral symptoms. PH80 also showed significant improvement in symptoms as early as Day 4 and continuing to Day 6. Headache was the most common adverse event. The results suggest a potential treatment option for PMDD and reinforce the potential of PH80 in women's healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
clinical trial
-
Rhea-AI Summary
Vistagen and Fuji Pharma enter into a time-limited agreement for exclusive negotiation regarding a potential license for Vistagen's PH80 in Japan. Fuji will pay $1.5 million for exclusive rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Rhea-AI Summary
Vistagen appoints Cindy Anderson as CFO, succeeding Jerrold Dotson who is retiring. Anderson brings almost two decades of financial and operating strength from her experiences in the biotechnology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.68%
Tags
management
-
Rhea-AI Summary
Vistagen reports positive Phase 3 results for fasedienol nasal spray in social anxiety disorder, plans for Phase 2B development of itruvone nasal spray in major depressive disorder, and positive Phase 2A results for PH80 nasal spray in vasomotor symptoms. The company also provides a corporate update and financial results for Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.63%
Tags
earnings clinical trial
-
Rhea-AI Summary
AffaMed Therapeutics and Vistagen Therapeutics announced positive top-line results from their Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol nasal spray in adults with social anxiety disorder. The trial met its primary endpoint, showing a statistically significant reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo during a public speaking challenge. The trial also met its secondary endpoint, demonstrating a statistically significant difference in the proportion of responders between fasedienol and placebo as measured by the Clinical Global Impressions Improvement (CGI-I) scale. Fasedienol was well-tolerated and had a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
partnership clinical trial
Rhea-AI Summary
Vistagen to host conference call and webcast on August 10, 2023, to provide corporate update and report Q1 2024 results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
conferences earnings
-
Rhea-AI Summary
Vistagen (NASDAQ: VTGN) announces positive Phase 3 results for fasedienol nasal spray in social anxiety disorder. Statistically significant reduction in SUDS score (p=0.015) and proportion of responders (p=0.033) compared to placebo. Fasedienol well-tolerated with no severe AEs reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
676.79%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
VistaGen Therapeutics Inc

Nasdaq:VTGN

VTGN Rankings

VTGN Stock Data

142.69M
15.25M
0.17%
63.16%
4.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About VTGN

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.